|
Market Closed -
Euronext Bruxelles
16:55:00 18/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 217.30 EUR | +0.88% |
|
-3.93% | -8.93% |
| 04:27pm | UCB: An unimpressive upgrade-led correction opens a rare opportunity |  |
| 08-11 | Berenberg Adjusts UCB Forecasts After H1 Beat; Buy Reaffirmed | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 47.57B | |||||
| 80.48B | |||||
| 50.63B | |||||
| 45.84B | - | ||||
| 30.9B | |||||
| 25.73B | - |
- Stock Market
- Stocks
- UCB Stock
- Charts UCB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
